Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONT: cFMT in Newly Diagnosed Chronic Inflammatory Diseases
NCT04924270Phase 2Recruiting
- Sponsor
- University Hospital Odense
- Start
- Dec 2023
- Primary completion
- Mar 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic fecal microbiota in rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and 3 more (2 arms), sponsored by University Hospital Odense. Primary endpoint: Physical Component Summary score of the Short Form Health Survey (SF-36) at 8 weeks. Started Dec 2023; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)psoriatic arthritis (PsA)pulmonary sarcoidosisCrohn's disease
Beyond the preview
Go deeper on NCT04924270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924270.